What is aTyr Pharma?
aTyr Pharma is a biotherapeutics enterprise dedicated to the discovery and development of novel medicines derived from newly identified biological pathways. The company's core research focuses on the extracellular functionality and signaling mechanisms of tRNA synthetases. By leveraging a robust global intellectual property portfolio, aTyr is developing a pipeline of protein compositions targeting these pathways. Its lead clinical-stage candidate, efzofitimod, is specifically engineered to bind to the neuropilin-2 receptor, providing a targeted mechanism to downregulate immune engagement in complex inflammatory lung conditions. This scientific focus places aTyr at the intersection of molecular biology and therapeutic innovation, aiming to address unmet medical needs through precision medicine.
How much funding has aTyr Pharma raised?
aTyr Pharma has raised a total of $340.3M across 9 funding rounds:
Series B
$10.5M
Series C
$23M
Series D
$49M
Debt
$10M
Series E
$76M
Stock Offering
$86M
Debt
$20M
Share Placement
$45.8M
Share Placement
$20M
Series B (2007): $10.5M with participation from Polaris Partners, Alta Partners, Imagene, and Cardinal Partners
Series C (2010): $23M led by Alta Partners, Domain Associates, Polaris Ventures, and Cardinal Partners
Series D (2013): $49M supported by Alta Partners, Polaris Partners, Cardinal Partners, and Domain Associates
Debt (2013): $10M featuring Silicon Valley Bank
Series E (2015): $76M backed by Polaris Partners, Sphera Global Healthcare, Deerfield, Cardinal Partners, EcoR1 Capital, T. Rowe Price Associates, Sofinnova Ventures, Federated Investors, Alta Partners, Rock Springs Capital Management, and Domain Associates
Stock Issuance/Offering (2015): $86M with participation from Undisclosed
Debt (2016): $20M led by Silicon Valley Bank and Solar Capital
Share Placement (2017): $45.8M supported by EcoR1 Capital, Redmile Group, and Viking Global Investors
Share Placement (2020): $20M featuring Aspire Capital Fund
Key Investors in aTyr Pharma
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and resources for growth.
Cardinal Partners
Cardinal Partners is a leading venture capital partnership focused exclusively on healthcare investing, often acting as a lead investor in early-stage financing rounds to drive innovation.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies that challenge existing medical paradigms.
What's next for aTyr Pharma?
Looking ahead, aTyr Pharma is poised to leverage its established capital base to accelerate the clinical development of efzofitimod. The strategic focus remains on validating the efficacy of its lead candidate in inflammatory lung disease, a critical milestone that will likely dictate the company's future valuation and potential for further commercial partnerships. As the firm continues to refine its research into tRNA synthetase biology, the emphasis will shift toward scaling clinical operations and potentially expanding the therapeutic application of its protein-based compositions. Sustained investment from top-tier healthcare-focused venture firms suggests a long-term commitment to the company's vision of transforming patient outcomes through fundamental biological discovery.
See full aTyr Pharma company page
